Physician profile
Nelson K Henry
NPI 1740364116
$13,311.36
in general payments reported to CMS, 2019-2025
44 companies · $2,308 in 2025
The $2,308 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,122 · 2020: $1,461 · 2021: $1,655 · 2022: $2,126 · 2023: $2,294 · 2024: $2,347 · 2025: $2,308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,948.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,724.18 | 2019-2025 | |
| Amgen INC. | $1,152.33 | 2019-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $1,086.72 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $1,081.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $965.87 | 2020-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $917.93 | 2020-2025 | |
| Glaxosmithkline, LLC. | $867.68 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $719.48 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Libre |
| Novartis Pharmaceuticals Corporation | $440.39 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $407.20 | 2019-2024 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.11 | 2019-2025 | Jardiance, Tradjenta |
| Allergan, INC. | $384.74 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $338.97 | 2019-2025 | Fanapt, Hetlioz |
| Esperion Therapeutics, INC. | $276.77 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $261.68 | 2022-2025 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $250.02 | 2019-2022 | |
| Astellas Pharma US INC | $233.47 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $213.92 | 2019-2025 | Lagevrio |
| Biohaven Pharmaceutical Holding Company LTD. | $185.30 | 2022 | |
| Sanofi-Aventis U.S. LLC | $152.00 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $146.11 | 2023-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $109.32 | 2022-2024 | Rexulti, Nuedexta |
| Ibsa Pharma INC. | $104.72 | 2022-2025 | Licart, Tirosint, Flector |
| Exact Sciences Corporation | $99.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $93.24 | 2023-2024 | Yupelri |
| Baxter Healthcare | $86.42 | 2023 | Hillrom - Cardiac Ambulatory Monitor, Hillrom - Carnation Ambulatory Monitor |
| Kowa Pharmaceuticals America, INC. | $85.44 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $85.03 | 2019-2024 | Eliquis |
| Boston Scientific Corporation | $79.91 | 2019-2024 | |
| Lundbeck LLC | $49.18 | 2022-2025 | Rexulti |
| Philips North America LLC | $41.01 | 2024 | (Ck6) Holter |
| Janssen Pharmaceuticals, INC | $33.56 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.28 | 2022 | |
| Dexcom, INC. | $24.58 | 2024 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $23.59 | 2024 | |
| Dynavax Technologies Corporation | $21.38 | 2024 | Heplisav-B |
| Sanofi Pasteur INC. | $20.08 | 2023 | |
| Genentech USA, INC. | $18.97 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $18.36 | 2025 | Opsumit, Uptravi |
| Insulet Corporation | $18.31 | 2021 | |
| Insightec,INC | $17.19 | 2024 | Exablate |
| Avanir Pharmaceuticals, INC. | $15.87 | 2019 | |
| Ardelyx, INC. | $14.79 | 2024 | Ibsrela |
| Medtronic, INC. | $14.47 | 2025 | Inceptiv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.